Vascular hemostatic disease

disease
On this page

Also known as disorder, vascular hemostaticdisorders, vascular hemostatichemostatic disorderhemostatic disorder, vascularhemostatic disorders, vascularvascular hemostatic disordervascular hemostatic disorders

Summary

Vascular hemostatic disease (MONDO:0003159) is a disease and 21 clinical trials. Top therapeutic interventions include sodium chloride, recombinant human thrombopoietin, and taniraleucel. A subtype of hemorrhagic disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

  • Clinical trials: 21

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical namevascular hemostatic disease
Mondo IDMONDO:0003159
MeSHD020141
DOIDDOID:484
SNOMED CT21112004
UMLSC0600502
MedGen154721
GARD0023389
Is cancer (heuristic)no

Also known as: disorder, vascular hemostatic · disorders, vascular hemostatic · hemostatic disorder · hemostatic disorder, vascular · hemostatic disorders, vascular · vascular hemostatic disorder · vascular hemostatic disorders

Disease family

This is a subtype of hemorrhagic disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › hematologic disorderhemorrhagic diseasevascular hemostatic disease

Related subtypes (27): inherited bleeding disorder, platelet-type, factor VII deficiency, factor X deficiency, purpura, congenital factor V deficiency, congenital high-molecular-weight kininogen deficiency, congenital factor XII deficiency, alpha-2-plasmin inhibitor deficiency, hemophilia A, hemophilia B, East Texas bleeding disorder, congenital factor XI deficiency, inherited prekallikrein deficiency, congenital plasminogen activator inhibitor type 1 deficiency, thrombomodulin-related bleeding disorder, congenital vitamin K-dependent coagulation factors deficiency, hemorrhagic disease due to alpha-1-antitrypsin Pittsburgh mutation, multiple sclerosis-ichthyosis-factor VIII deficiency syndrome, congenital factor XIII deficiency, congenital fibrinogen deficiency, combined deficiency of factor V and factor VIII, acquired hemophilia, fetal and neonatal alloimmune thrombocytopenia, hereditary von Willebrand disease, acquired von willebrand syndrome, prothrombin deficiency, hemophilia B leyden

Subtypes (2): Shwartzman phenomenon, cavernous hemangioma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated or in trials for this disease

1 approved drug — disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

DrugStatus
Idecabtagene VicleucelApproved (phase 4)

Clinical trials & evidence

Clinical trials

Clinical trials: 21.

Phase distribution (across all retrieved trials)

PhaseTrials
Not specified16
PHASE13
PHASE41
PHASE1/PHASE21

Top trials by phase / activity

NCTPhaseStatusTitle
NCT01919840PHASE4TERMINATEDBlood Products Transfusion in Cardiac Surgery After the Implementation of a Coagulation Monitoring System at Patient Bedside: Thromboelastometry Versus Standard Transfusion Protocol
NCT03806556PHASE1/PHASE2TERMINATEDA Pediatric Trial Using Tranexamic Acid in Thrombocytopenia
NCT06271252PHASE1RECRUITINGA Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study
NCT07075185PHASE1RECRUITINGA Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
NCT04309084PHASE1UNKNOWNNatural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma
NCT06242353Not specifiedNOT_YET_RECRUITINGCoagulopathy in Childhood Acute Lymphoblastic Leukaemia
NCT06328647Not specifiedACTIVE_NOT_RECRUITINGQuantra Point-of-Care Hemostasis Monitoring
NCT06571552Not specifiedRECRUITINGCoagulation Disorders Secondary to Two Plasmapheresis Techniques (Double Filtration Plasmapheresis vs. PFS). Descriptive Pilot Study.
NCT02281240Not specifiedUNKNOWNHemostatic Complications in Hematopoietic Stem Cell Transplantation
NCT03281252Not specifiedUNKNOWNA Prospective Study of Evaluation of Minor Bleeding and Utility of Bleeding Criteria in Acute-on-chronic Liver Failure Patients in China
NCT03555383Not specifiedCOMPLETEDIndividualized Multimodal Hemostasis Evaluation Pyramid (IMHOTEP)
NCT03756948Not specifiedCOMPLETEDViscoelastic Tests-Guided Therapy In Liver Transplantation
NCT04179357Not specifiedUNKNOWNHemostatic Disorders on Intensive Care Patients.
NCT04499612Not specifiedCOMPLETEDInfluence of Cardiac Implantable Electronic Devices on the Hemostatic System
NCT04600609Not specifiedCOMPLETEDExamining the Experiences of Children With Blood Disorders
NCT04650529Not specifiedUNKNOWNGyeongsang National University Hospital Registry
NCT04729946Not specifiedTERMINATEDClinical and Urgent Colonoscopy Outcomes Using the Pure-Vu® Cleansing System
NCT04757285Not specifiedCOMPLETEDCopeptin and Psychological Stress of Medic During COVID-19 Pandemic
NCT04762576Not specifiedUNKNOWNThrombin in Cardiac Surgery
NCT05476458Not specifiedUNKNOWNTo Evaluate Efficacy of Red Dichromatic Imaging (RDI) in Achieving Hemostasis During POEM Using GF 1500 UGI Scope
NCT05775731Not specifiedUNKNOWNMarkers of Inflammation and of the Pro-thrombotic State in Hospital Shift and Day Workers

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
SODIUM CHLORIDE41
RECOMBINANT HUMAN THROMBOPOIETIN31
TANIRALEUCEL11